- Needham upgraded Penumbra Inc PEN to Buy from Hold, with a price target of $244.
- The analyst notes that management indicated PEN is seeing stronger growth in 3Q22 due to an improvement in hospital staffing, share gains, or a combination of these.
- Penumbra recently announced European approval for RED Reperfusion Catheters, which are part of the company's Penumbra System, a fully integrated mechanical aspiration thrombectomy system designed to restore blood flow in acute ischemic stroke patients.
- Related: With Sustained Double-Digit Growth Profile, RBC Starts Coverage On This MedTech Stock.
- The analyst believes the international RED catheter launches should help to drive faster stroke growth as soon as 4Q22.
- Needham also writes that the upcoming intelligent aspiration launches should drive faster growth starting in 2023.
- In its Neuro business, PEN plans to launch Thunderbolt in 2H23 after it completes its THUNDER IDE trial, which is now underway.
- In its Vascular business, the company plans to launch its Lightning Flash and Lightning Bolt products in 2023, which are new versions of its intelligent aspiration system.
- The analyst expects the Lightning systems to drive growth through increased thrombectomy market penetration and market share gains.
- Price Action: PEN shares are up 2.62% at $202.67 on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in